Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $1.3 million.

  • Champions Oncology's Change in Account Payables rose 44319.37% to $1.3 million in Q4 2025 from the same period last year, while for Oct 2025 it was $920000.0, marking a year-over-year increase of 18930.82%. This contributed to the annual value of -$1.7 million for FY2025, which is 47612.9% down from last year.
  • Latest data reveals that Champions Oncology reported Change in Account Payables of $1.3 million as of Q4 2025, which was up 44319.37% from $411000.0 recorded in Q3 2025.
  • Champions Oncology's Change in Account Payables' 5-year high stood at $2.1 million during Q4 2022, with a 5-year trough of -$2.0 million in Q1 2021.
  • For the 5-year period, Champions Oncology's Change in Account Payables averaged around $103150.0, with its median value being $141500.0 (2021).
  • Within the past 5 years, the most significant YoY rise in Champions Oncology's Change in Account Payables was 144328.36% (2022), while the steepest drop was 63557.05% (2022).
  • Quarter analysis of 5 years shows Champions Oncology's Change in Account Payables stood at $134000.0 in 2021, then surged by 1443.28% to $2.1 million in 2022, then crashed by 159.19% to -$1.2 million in 2023, then soared by 68.79% to -$382000.0 in 2024, then soared by 443.19% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q4 2025, $411000.0 for Q3 2025, and -$614000.0 during Q2 2025.